Hormone therapy for locally advanced prostate cancer
04 April 2011
Recent research has reported a benefit for hormone therapy prior to receiving radiotherapy in men with locally advanced prostate cancer.
The study was a randomised controlled trial in which men were randomly assigned to receive androgen deprivation therapy (ADT) or no additional treatment, prior to receiving radiotherapy.
The study found that the men who received ADT had a 11.4% chance of dying from prostate cancer over the following ten years. This compares to 22.0% amongst men who received radiotherapy alone.
On this basis, we would expect ADT to prevent around one in ten deaths from prostate cancer after ten years.
Note that this highly significant finding is consistent with current guidelines for management of locally advanced prostate cancer.
Find out more
- Background information about locally advanced prostate cancer and androgen deprivation therapy on UK Prostate Link
- Read the CancerHelp UK and NHS Choices review
- Get the original research: Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. The Lancet Oncology, Early Online Publication, 25 March 2011
Page last edited: 02 October 2011